Avalo Therapeutics Inc (AVTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Sales | 643 | 475 | 896 | 14,949 | 1,033 |
| Cost of Goods | 708 | 551 | 619 | 528 | 1,567 |
| Gross Profit | -65 | -76 | 277 | 14,421 | -534 |
| Operating Expenses | 7,793 | 9,267 | 9,750 | 10,854 | 11,861 |
| Operating Income | -7,150 | -8,792 | -8,854 | 4,095 | -11,828 |
| Interest Expense | 0 | 0 | 949 | 898 | 1,154 |
| Other Income | -1,036 | -1,155 | 0 | 0 | 0 |
| Pre-tax Income | -8,186 | -9,947 | -9,803 | 3,197 | -12,982 |
| Income Tax | 7 | 8 | 9 | 5 | 5 |
| Net Income Continuous | -8,193 | -9,955 | -9,812 | 3,192 | -12,987 |
| Net Income | $-8,193 | $-9,955 | $-9,812 | $3,192 | $-12,987 |
| EPS Basic Total Ops | -140.73 | -204.00 | -255.86 | 80.95 | -328.57 |
| EPS Basic Continuous Ops | -141.26 | -203.81 | -255.93 | 80.74 | -328.92 |
| EPS Diluted Total Ops | -140.73 | -204.00 | -255.86 | 80.95 | -328.57 |
| EPS Diluted Continuous Ops | -141.26 | -203.81 | -255.93 | 80.73 | -328.92 |
| EPS Diluted Before Non-Recurring Items | -140.48 | -202.38 | -247.62 | N/A | N/A |
| EBITDA(a) | $-6,760 | $-8,409 | $-8,470 | $4,483 | $-11,462 |